DispersinBĀ® Patent issues in Australia

January 25, 2010

WINNIPEG, Manitoba (January 20, 2010) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled “Compositions and methods for enzymatic detachment of bacterial and fungal biofilms” by IP Australia (Australian Patent and Trademark Office). Australia is the third country to issue a patent covering Kane Biotech’s DispersinB® anti-biofilm technology.

This patent claims the gene encoding DispersinB® enzyme and also the amino acid sequence of the enzyme. In addition, the claims include: (i) a method of producing DispersinB®, (ii) pharmaceutical compositions comprising DispersinB® and an antibody or an antibiotic/antimicrobial, (iii) methods of administration, and (iv) applications in medical devices, wound care and oral care. Kane Biotech and many independent researchers around the world have demonstrated the in vitro and in vivo efficacy of the DispersinB® antibiofilm enzyme in numerous studies.

“We are very pleased that our DispersinB® patents are beginning to issue around the World and we now have patent protection in the United States, New Zealand and Australia, with pending patents in other countries as well”, stated Gord Froehlich, President and CEO of Kane Biotech.
About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

For more information, please contact:
Gord Froehlich
President & Chief Executive Officer
Kane Biotech Inc.
204-477-7592 phone
204-453-1314 fax

Share This Story